aTyr Pharma (NASDAQ:ATYR) Given Sell (D-) Rating at Weiss Ratings

Key Points

• aTyr Pharma has been given a Sell (D-) rating by Weiss Ratings, indicating a bleak outlook for the company.
• Analysts’ opinions vary, with Jefferies raising their price target to $17.00 while Cantor Fitzgerald downgraded the stock to a neutral rating.
• The company's stock recently traded at $1.00 with a market cap of $97.99 million and a consensus price target of $23.25.

aTyr Pharma (NASDAQ:ATYR - Get Free Report)'s stock had its "sell (d-)" rating restated by analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Several other analysts also recently commented on ATYR. Jefferies Financial Group raised their price objective on shares of aTyr Pharma from $9.00 to $17.00 and gave the company a "buy" rating in a research report on Friday, August 22nd. Cantor Fitzgerald cut shares of aTyr Pharma from an "overweight" rating to a "neutral" rating in a research note on Monday, September 15th. Leerink Partnrs cut shares of aTyr Pharma from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 15th. Wall Street Zen cut shares of aTyr Pharma from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Finally, Wells Fargo & Company reaffirmed an "equal weight" rating on shares of aTyr Pharma in a research note on Monday, September 15th. One analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, aTyr Pharma has an average rating of "Hold" and a consensus price target of $23.25.

aTyr Pharma Stock Performance

ATYR traded up $0.16 during trading on Wednesday, hitting $1.00. The company's stock had a trading volume of 11,776,233 shares, compared to its average volume of 4,805,756. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to-equity ratio of 0.01. aTyr Pharma has a one year low of $0.68 and a one year high of $7.29. The firm has a market cap of $97.99 million, a PE ratio of -1.25 and a beta of 0.79. The business's 50 day simple moving average is $3.75 and its 200-day simple moving average is $4.07.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.04). As a group, sell-side analysts predict that aTyr Pharma will post -0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On aTyr Pharma

Large investors have recently modified their holdings of the business. Oxford Asset Management LLP bought a new position in shares of aTyr Pharma during the 2nd quarter worth approximately $70,000. Octagon Capital Advisors LP increased its position in shares of aTyr Pharma by 7.5% in the 2nd quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company's stock valued at $19,367,000 after acquiring an additional 268,000 shares during the period. BNP Paribas Financial Markets acquired a new position in aTyr Pharma during the second quarter valued at $99,000. California State Teachers Retirement System acquired a new stake in aTyr Pharma during the second quarter worth about $28,000. Finally, Raymond James Financial Inc. boosted its holdings in aTyr Pharma by 79.3% during the second quarter. Raymond James Financial Inc. now owns 24,839 shares of the company's stock worth $126,000 after buying an additional 10,989 shares in the last quarter. Institutional investors own 61.72% of the company's stock.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.